News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
692,532 Results
Type
Article (39383)
Company Profile (247)
Press Release (652902)
Section
Business (204028)
Career Advice (2005)
Deals (35405)
Drug Delivery (93)
Drug Development (80940)
Employer Resources (169)
FDA (16133)
Job Trends (14828)
News (344877)
Policy (32473)
Tag
Academia (2535)
Alliances (49314)
Alzheimer's disease (1314)
Approvals (16117)
Artificial intelligence (199)
Bankruptcy (357)
Best Places to Work (11637)
Biotechnology (175)
Breast cancer (225)
Cancer (1710)
Cardiovascular disease (128)
Career advice (1669)
CAR-T (121)
Cell therapy (353)
Clinical research (65243)
Collaboration (659)
Compensation (370)
COVID-19 (2563)
C-suite (160)
Data (1629)
Diabetes (211)
Diagnostics (6282)
Earnings (85436)
Employer resources (146)
Events (110863)
Executive appointments (564)
FDA (17034)
Funding (602)
Gene therapy (245)
GLP-1 (648)
Government (4357)
Healthcare (18767)
Infectious disease (2674)
Interviews (310)
IPO (16461)
Job creations (3627)
Job search strategy (1420)
Layoffs (437)
Legal (7885)
Lung cancer (255)
Manufacturing (235)
Medical device (13261)
Medtech (13266)
Mergers & acquisitions (19319)
Metabolic disorders (548)
Neuroscience (1715)
NextGen: Class of 2025 (6509)
Non-profit (4475)
Northern California (2090)
Obesity (306)
Opinion (194)
Patents (162)
People (56829)
Phase I (20315)
Phase II (28744)
Phase III (21397)
Pipeline (711)
Postmarket research (2562)
Preclinical (8575)
Radiopharmaceuticals (241)
Rare diseases (321)
Real estate (5897)
Regulatory (21917)
Research institute (2312)
Resumes & cover letters (349)
Southern California (1791)
Startups (3567)
United States (18436)
Vaccines (611)
Weight loss (208)
Date
Last 7 days (593)
Last 30 days (2464)
Last 365 days (34384)
2025 (4427)
2024 (35217)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54083)
2019 (46539)
2018 (35019)
2017 (32111)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (716)
Arizona (211)
Asia (37505)
Australia (6132)
California (4761)
Canada (1715)
China (392)
Colorado (217)
Connecticut (230)
Europe (80385)
Florida (688)
Georgia (165)
Illinois (455)
Indiana (259)
Japan (121)
Maryland (739)
Massachusetts (3602)
Michigan (198)
Minnesota (334)
New Jersey (1347)
New York (1359)
North Carolina (833)
Northern California (2090)
Ohio (173)
Pennsylvania (1098)
South America (1093)
Southern California (1791)
Texas (701)
Utah (143)
Washington State (467)
692,532 Results for "visterra inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Scailyte and Visterra Partner to Advance Autoimmune Disease Research
December 17, 2024
·
1 min read
Policy
Sibeprenlimab Receives U.S. FDA Breakthrough Therapy Designation for the Treatment of Immunoglobulin A Nephropathy
Otsuka Pharmaceutical Development & Commercialization, Inc., ; Otsuka Pharmaceutical, Co. Ltd. ; and Visterra, Inc., an Otsuka group company announce that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation for the investigational drug sibeprenlimab for the treatment of immunoglobulin A nephropathy.
February 16, 2024
·
7 min read
Drug Development
New England Journal of Medicine Publishes Complete Results of Positive Phase 2 Trial of Sibeprenlimab in Treatment of Immunoglobulin A Nephropathy (IgAN)
Otsuka Pharmaceutical Development & Commercialization, Inc. and Visterra Inc., today announced that the full results of a Phase 2 trial of sibeprenlimab (VIS649) for treatment of immunoglobulin A nephropathy (IgAN; Berger’s disease) have been published in the New England Journal of Medicine.
November 2, 2023
·
8 min read
Press Releases
Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.
February 12, 2025
·
6 min read
Press Releases
Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.
January 23, 2025
·
5 min read
Press Releases
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Engage BTIG as Financial Advisor
February 3, 2025
·
7 min read
Press Releases
NanoViricides, Inc. Has Filed its Quarterly Report
February 20, 2025
·
12 min read
Press Releases
Windtree Therapeutics, Inc. Announces Reverse Stock Split
February 19, 2025
·
7 min read
Press Releases
111, Inc. Regains Compliance with NASDAQ Requirement
February 11, 2025
·
3 min read
Press Releases
Kronos Advanced Technologies Inc. ($KNOS) Confirms Ownership and Shareholder Updates for KronosMD, Inc.
January 27, 2025
·
13 min read
1 of 69,254
Next
